Staging in childhood lymphoma: Differences between FDG-PET and CT

NuklearMedizin

Volumn 44, Issue 1, 2005, Pages 1-7

  Hermann, Sven ^a   Wormanns, D ^a   Pixberg, M ^a   Hunold, A ^a   Heindel, W ^a   Jurgens H ^a   Schober, O ^a   Franzius, C ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Hodgkin; Lymphoma; Paediatrics; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ARTICLE; BEHAVIOR MODIFICATION; CANCER PATIENT; CANCER STAGING; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPH NODE BIOPSY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 14644398541     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623923     Document Type: Article

References (30)

1. Arita T, Kuramitsu T, Kawamura M et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995; 50: 1267-9.
2. Brink I, Reinhardt MJ, Hoegerle S et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42: 591-5.
3. Buchmann I, Reinhardt M, Elsner K et al. 2-(fluorine-18)fluoro-2-deoxy-D- glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889-99.
4. 18F-FDG PET/CT. J Nucl Med 2003; 44: 170-6.
5. Franzius C, Schober O. Assessment of therapy response by FDG PET in pediatric patients. Q J Nucl Med 2003; 47: 41-5.
6. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist 2003; 8: 438-47.
7. Gross BH, Glazer GM, Orringer MB et al. Bronchogenic carcinoma metastatic to normalsized lymph nodes: frequency and significance. Radiology 1988; 166: 71-4.
8. Hull MC, Morris CG, Pepine CJ et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831-7.
9. Deutsche Krebsgesellschaft: Kurzgefasste Interdisziplinäire Leitlinien. 3. Auflage, Zuckerschwerdt 2002.
10. Jabour BA, Choi Y, Hoh CK et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186: 27-35.
11. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27: 1564-78.
12. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7.
13. Leung W, Sandlund JT, Hudson MM et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001; 92: 1959-66.
14. 18F-FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29: 1155-65.
15. Ng AK, Bernardo MVP, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-96.
16. O'Doherty MJ, Macdonald EA, Barrington SF et al. Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) 2002; 14: 415-26.
17. Partridge S, Timothy A, O'Doherty MJ et al. 2-Fluorine-18-fluoro-2-deoxy- D-glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-9.
18. Pastore G, Magnani C, Verdecchia A et al. Survival of childhood lymphomas in Europe, 1978-1992: a report from the EUROCARE study. Eur J Cancer 2001; 37: 703-10.
19. Piepsz A, Hahn K, Roca I et al. A radiopharmaceuticals schedule for imaging in paediatrics. Paediatric Task Group European Association Nuclear Medicine. Eur J Nucl Med 1990; 17: 127-9.
20. Pond GD, Castellino RA, Horning S et al. Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management. Radiology 1989; 170: 159-64.
21. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, Onko-PET III. 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-23.
22. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S89-96.
23. Ries L, Smith M, Gurney J et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Publication 1999.
24. Schiepers C, Filmont J, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S82-8.
25. Schoder H, Larson SM, Yeung HWD. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45 (Suppl 1): 72S-81.
26. 18F-FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S97-105.
27. 18F-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38: 193-221.
28. Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-5.
29. 18F-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations. Klin Pädiatr 2003; 215: 146-50.
30. 18F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003; 44: 1789-96.